Evaluation of reporting quality of cohort studies using real-world data based on RECORD: systematic review

[1] Eichler H-G(2021)Randomized controlled trials Versus Real World evidence: neither Magic nor myth Clin Pharmacol Ther 109 1212-8

[2] Pignatti F(2019)Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation Br J Clin Pharmacol 85 1874-7

[3] Schwarzer-Daum B(2020)Real-world evidence and regulatory drug approval Nat Rev Clin Oncol 17 271-2

[4] Hidalgo-Simon A(2022)Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions Nat Commun 13 5126-22

[5] Eichler I(2017)Reporting to improve reproducibility and facilitate Validity Assessment for Healthcare Database Studies V1.0 Value Health J Int Soc Pharmacoeconomics Outcomes Res 20 1009-9

[6] Arlett P(2011)Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data J Clin Epidemiol 64 821-33

[7] Breckenridge AM(2018)Real-world evidence: useful in the Real World of US payer decision making? How? When? And what studies? Value Health J Int Soc Pharmacoeconomics Outcomes Res 21 326-10

[8] Breckenridge RA(2015)The REporting of studies conducted using Observational routinely-collected health data (RECORD) statement PLoS Med 12 e1001885-9

[9] Peck CC(2018)The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) BMJ 363 k3532-24

[10] Raphael MJ(2016)Guidelines for good pharmacoepidemiology practice (GPP) Pharmacoepidemiol Drug Saf 25 2-11

[1] Eichler H-G(2021)Randomized controlled trials Versus Real World evidence: neither Magic nor myth Clin Pharmacol Ther 109 1212-8

[2] Pignatti F(2019)Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation Br J Clin Pharmacol 85 1874-7

[3] Schwarzer-Daum B(2020)Real-world evidence and regulatory drug approval Nat Rev Clin Oncol 17 271-2

[4] Hidalgo-Simon A(2022)Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions Nat Commun 13 5126-22

[5] Eichler I(2017)Reporting to improve reproducibility and facilitate Validity Assessment for Healthcare Database Studies V1.0 Value Health J Int Soc Pharmacoeconomics Outcomes Res 20 1009-9

[6] Arlett P(2011)Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data J Clin Epidemiol 64 821-33

[7] Breckenridge AM(2018)Real-world evidence: useful in the Real World of US payer decision making? How? When? And what studies? Value Health J Int Soc Pharmacoeconomics Outcomes Res 21 326-10

[8] Breckenridge RA(2015)The REporting of studies conducted using Observational routinely-collected health data (RECORD) statement PLoS Med 12 e1001885-9

[9] Peck CC(2018)The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE) BMJ 363 k3532-24

[10] Raphael MJ(2016)Guidelines for good pharmacoepidemiology practice (GPP) Pharmacoepidemiol Drug Saf 25 2-11